Erk7 and erk8, novel diagnostic markers for cancer

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 9/12 (2006.01) C07H 21/04 (2006.01) C12N 15/54 (2006.01)

Patent

CA 2529559

The present invention is directed in part to the discovery of a novel signal transduction pathway that regulates estrogen responsiveness. Human extracellular signal-regulated kinase 8 (ERK8) has been discovered by applicants to preferentially enhance the destruction of ER.alpha. , and loss of ERK8 is correlated with breast cancer progression. Thus monitoring the expression of ERK8 can be used as a diagnostic and therapeutic indicator of cancer and cancer progression.

L'invention concerne en partie la découverte d'un nouvelle voie de transduction de signal régulant la faculté de réponse d'oestrogène. On a découvert que la kinase 8 humaine à régulation de signal extracellulaire (ERK8) augmentait préférentiellement la destruction de ER.alpha., et que la perte de ERK8 était en corrélation avec le développement du cancer du sein. Ainsi, le contrôle de l'expression de ERK8 peut être utilisé comme indicateur de diagnostic et comme thérapeutique du cancer et du développement du cancer.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Erk7 and erk8, novel diagnostic markers for cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Erk7 and erk8, novel diagnostic markers for cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erk7 and erk8, novel diagnostic markers for cancer will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1959444

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.